A Peptide Marketed for Tanning Linked to Increased Skin Cancer Risk, Study Finds

A peptide marketed for promoting tanning has been linked to an increased risk of skin cancer, according to a recent study published in the *Journal of Investigative Dermatology*. The findings, which contradict claims by the product’s manufacturers, suggest the compound may accelerate the growth of melanoma cells in laboratory models, according to the research team at the University of Colorado Anschutz Medical Campus.

What Is the Peptide in Question?

The peptide, known as Melanotan II, is a synthetic compound designed to stimulate melanin production, the pigment responsible for skin darkening. Initially developed in the 1990s as a potential treatment for白癜风 (vitiligo), it has since gained popularity in some circles as a “sunless tanning” alternative. However, its use remains unapproved by the U.S. Food and Drug Administration (FDA), with the agency warning in 2021 that products containing the peptide “lack proven safety and efficacy.”

Manufacturers often market Melanotan II as a way to achieve a “base tan” without UV exposure, but the new study highlights significant risks. “The data clearly show that this compound interacts with melanoma cells in ways that could worsen outcomes,” said Dr. Emily Carter, a co-author of the study and a dermatologist at the University of Colorado. “We don’t see any medical benefit that outweighs these risks.”

What Are the Health Risks?

The study, which analyzed the effects of Melanotan II on human melanoma cells in vitro, found that the peptide increased the cells’ ability to proliferate and resist programmed cell death. While the findings do not prove the compound causes cancer in humans, they align with earlier concerns raised by the American Academy of Dermatology (AAD). In a 2022 statement, the AAD warned that “unregulated tanning products like Melanotan II may pose serious health risks, including skin cancer.”

Dr. Marcus Lee, a board-certified dermatologist not involved in the study, emphasized the lack of oversight. “These products are often sold online without safety testing,” he said. “Even if they don’t directly cause cancer, they could interfere with early detection or treatment of existing lesions.”

Why Did the Study Spark Concern?

The research team noted that Melanotan II’s mechanism of action—activating melanocortin receptors—overlaps with pathways linked to melanoma progression. “Melanocortin receptors are known to play a role in cell growth and survival,” said Dr. Carter. “When activated by this peptide, they may inadvertently fuel tumor development.”

The study also cited a 2020 case report in *The Lancet Oncology* detailing a patient who developed melanoma after using a Melanotan II-containing product. While the case does not establish causation, it underscores the need for further research. The National Cancer Institute (NCI) has since launched a separate investigation into the long-term effects of the peptide, with results expected in 2025.

What Should Consumers Do?

Health authorities are advising caution. The FDA has issued multiple warnings against using unapproved tanning products, including Melanotan II, and encourages consumers to consult licensed dermatologists before trying any such compounds. “If you’re considering a tanning product, ask your doctor about safer alternatives,” said Dr. Lee. “Sunscreen, protective clothing, and avoiding peak UV hours remain the most effective ways to reduce skin cancer risk.”

For those already using the peptide, experts recommend regular skin examinations and vigilance for changes in moles or skin lesions. “Early detection is critical,” said Dr. Carter. “If you notice anything unusual, seek medical attention immediately.”

The study’s authors stress that their findings are preliminary and call for larger clinical trials to confirm the risks. In the meantime, they urge regulators to reevaluate the availability of Melanotan II and similar compounds. “Public health should come first,” said Dr. Carter. “We can’t afford to wait for more evidence when the stakes are this high.”